GLUE Monte Rosa Therapeutics, Inc.

$18.30 -0.46%

Healthcare · Biological Products, (No Diagnostic Substances)

Monte Rosa Therapeutics, Inc. (GLUE) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $1.5 billion. Shares last traded at $18.30, 29.0% below their 52-week high. Over the past year the stock is up 299.5%. Net profit margin is -31.2%, below the peer median of 6.3%. Revenue grew 63.5% year over year.

Market Cap

$1.5B

Shares Out

84.5M

EPS (TTM)

—

P/E Ratio

—

P/S Ratio

12.50

P/B Ratio

2.96

Dividend / Share

—

Dividend Yield

—

52-Week High

$25.75

52-Week Low

$4.12

Volume

61,646

Avg Vol (3m)

55,640.841

Performance

+6.93%

+4.04%

+13.92%

-1.88%

YTD

+19.65%

+299.45%

Chart

Full chart →

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)

51.57

SMA (50)

$18.67

SMA (200)

$15.84

Price vs SMA50

-2.02%

Price vs SMA200

+15.47%

ATR (14)

$1.52

Financials

Revenue

$124M

Net Income

$-39M

Gross Margin

—

Operating Margin

-43.8%

Net Margin

-31.2%

Return on Equity

-7.4%

Return on Assets

-5.2%

Current Ratio

9.54

Debt / Equity

0.41

Revenue Growth (YoY)

+63.5%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Biological Products, (No Diagnostic Substances) peers

GLUE vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers

12.50 / 5.21 med

+140% premium

Net margin vs peers

-31.2% / 6.3% med

below median

1–14 of 14


AMGN	Amgen	$182.1B	23.62	4.96	21.0%	-1.27%
GILD	Gilead Sciences	$153.5B	18.04	5.21	28.9%	-1.46%
RVMD	Revolution Medicines, Inc.	$34.6B	-30.62	—	—	+3.14%
BIIB	Biogen	$29.0B	22.44	2.93	13.1%	-1.15%
MRNA	Moderna	$25.4B	-8.99	—	—	+3.22%
NBIX	Neurocrine Biosciences Inc	$15.9B	33.24	5.56	16.7%	-0.48%
EXEL	Exelixis, Inc.	$13.1B	16.68	5.62	33.7%	-1.04%
KRYS	Krystal Biotech, Inc.	$10.2B	50.02	26.33	52.6%	+1.68%
TECH	Bio-Techne	$9.1B	123.61	7.44	6.0%	+5.36%
HALO	Halozyme Therapeutics, Inc.	$8.1B	25.67	5.82	22.7%	-0.03%
IBRX	Immunitybio, Inc.	$7.7B	-21.87	—	—	+5.01%
RGEN	Repligen Corp	$7.4B	152.27	10.08	6.6%	-1.20%
KYMR	Kymera Therapeutics, Inc.	$7.4B	23.88	—	—	+0.44%
PCVX	Vaxcyte, Inc.	$7.4B	-9688.00	—	—	+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.